In this study, we identify cerebrospinal fluid Neo1 as a biomarker for poor prognosis in SAH patients, linking BBB disruption to endothelial dysfunction mediated by astrocytic Neo1. This evidence concerns the gene NEO1 and endothelial dysfunction.